VEGFA and melanoma: The AVAST-M trial assessed the role of adjuvant bevacizumab (recombinant humanized monoclonal antibody directed against VEGF) in melanoma patients with resected stage IIB-C and IIIA, B and C, who received either adjuvant bevacizumab or standard follow-up [11].